This week in Family Medicine

Nov 15, 2026

Latest episode · 11 min
Editor’s pick

Intensive Blood-Pressure Control in Patients with Previous Ischemic Stroke.

In 4368 Brazilian adults with prior ischaemic stroke or TIA, a systolic target below 120 reduced major cardiovascular events versus below 140, though kidney function decline was more common.

New England Journal of Medicine · 2026 · PubMed

This week’s highlights

  1. 01Intensive Blood-Pressure Control in Patients with Previous Ischemic Stroke.

    In 4368 Brazilian adults with prior ischaemic stroke or TIA, a systolic target below 120 reduced major cardiovascular events versus below 140, though kidney function decline was more common.

    Sampaio Silva G et al. · New England Journal of Medicine · 2026

    PMID 43001741

  2. 02Intensive Blood-Pressure Lowering in Patients with Type 2 Diabetes.

    In 9476 Brazilian adults with type 2 diabetes and high cardiovascular risk, targeting systolic pressure below 120 versus below 140 did not significantly reduce major cardiovascular events.

    Santo K et al. · New England Journal of Medicine · 2026

    PMID 43001746

  3. 03Doxycycline and Risk for Pregnancy Loss : A Multi-database, Multi-indication Cohort Study.

    In United States claims data, first-trimester doxycycline for respiratory infection was associated with roughly 40 to 50 percent higher pregnancy loss risk than amoxicillin or macrolides, though residual confounding is possible.

    Winterstein AG et al. · Annals of Internal Medicine · 2026

    PMID 43002780

  4. 04Community health worker-led hypertension management with independent prescribing in rural Lesotho: a cluster-randomised non-inferiority trial.

    In rural Lesotho, community health workers independently prescribing antihypertensives were non-inferior to nurse-led facility care for maintaining blood pressure control at 12 months, with similar serious adverse events.

    Gerber F et al. · The Lancet Global Health · 2026

    PMID 43025432

  5. 05Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

    Withholding ACE inhibitors or ARBs on the morning of non-cardiac surgery in adults aged 60 to 80 reduced perioperative hypotension and vasopressor use without increasing 30-day complications or mortality.

    Yang Y et al. · BMJ · 2026

    PMID 43014822

  6. 06Drug Burden Index Stewardship to Deprescribe Anticholinergic or Sedative Drugs in Older Inpatients: A Stepped-Wedge Cluster Randomized Clinical Trial.

    A pharmacist-led Drug Burden Index stewardship bundle in Australian hospitals modestly increased deprescribing of anticholinergic and sedative drugs in older inpatients, but the effect faded once stewardship ended.

    Fujita K et al. · JAMA Internal Medicine · 2026

    PMID 43002427

  7. 07Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial.

    Adding thrice-weekly resistance exercise to tirzepatide for 40 weeks did not change weight or fat loss but reduced lean mass loss and increased muscle strength in 120 adults.

    Green DJ et al. · Nature Medicine · 2026

    PMID 43003902

  8. 08Use Vaginal Swabs, Not Urine, to Test for Gonorrhea and Chlamydia.

    A practice recommendation states that vaginal swabs are the most sensitive specimen for detecting gonorrhea and chlamydia in female patients and argues against routine urine testing.

    Lynn C et al. · Journal of the American Board of Family Medicine · 2026

    PMID 43025889

  9. 09Multicancer Detection Tests: Navigating Promise, Pitfalls, and the Path Forward for Primary Care.

    A special report finds evidence for blood-based multicancer detection tests immature, with insufficient data on mortality or quality of life, even as clinical uptake grows ahead of guidelines.

    Rubinstein WS et al. · Annals of Family Medicine · 2026

    PMID 43009314

  10. 10Development of recommendations to improve the identification and management of binge eating disorder and bulimia nervosa in primary care in the UK: a qualitative investigation.

    Interviews with 26 United Kingdom clinicians and people with lived experience identified education, primary care screening tools, referral pathways and co-designed national guidelines as priorities for binge eating disorder and bulimia care.

    Kozmér S et al. · BJGP Open · 2026

    PMID 43003664

Read the weekly briefing

This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.

This week: a lower blood pressure target after stroke cuts cardiovascular events, the same target shows no clear benefit in type 2 diabetes, and first-trimester doxycycline is linked to more pregnancy loss.

Welcome to This Week in Family Medicine. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.

Two blood pressure trials this week come from the same Brazilian research network, and they point in different directions. The first, OPTIMAL-STROKE, published in the New England Journal of Medicine and led by Sampaio Silva, was an open-label randomised trial at 30 sites in Brazil [1]. It enrolled 4368 adults with elevated blood pressure and a previous ischaemic stroke or transient ischaemic attack, and assigned them to a systolic target below 120 or below 140. The achieved difference between groups was about 13 millimetres of mercury. Over a median of just under four years, the composite of cardiovascular death, nonfatal heart attack, nonfatal stroke, or hospitalisation for unstable angina or heart failure occurred in about 11 percent of the intensive group and about 13.5 percent of the standard group, a relative reduction of roughly a fifth. Serious adverse events overall were similar. The composite kidney outcome, a sustained fall in estimated glomerular filtration rate by half or more or progression to end-stage disease, was more common with intensive treatment, and the abstract does not report results by baseline kidney function. The open-label design is the main limitation, since clinicians knew each patient's target. The trial adds randomised evidence specific to secondary stroke prevention in favour of a lower systolic target.

The companion trial, OPTIMAL-DIABETES, also in the New England Journal of Medicine and led by Santo, used the same targets and the same composite outcome in 9476 ethnically diverse adults in Brazil with type 2 diabetes, elevated blood pressure and high cardiovascular risk [2]. Just over sixty percent of participants were women. Achieved systolic pressure was about 122 in the intensive arm and about 135 in the standard arm. Over a median of four years, the primary outcome occurred in 6.0 percent of patients with intensive therapy and 6.7 percent with standard therapy, a difference that was not statistically significant. Serious adverse events were similar, at roughly fifteen percent in each group. The same lower target that reduced events after stroke did not reduce them in diabetes. Event rates in this trial were considerably lower than in the stroke trial, which limits the power to detect a modest benefit, and the open-label design again applies. The abstract does not report kidney outcomes or subgroup results. This trial adds a large, null randomised result to the question of intensive systolic targets in type 2 diabetes, and it sits in direct contrast with its sister trial in stroke.

In Annals of Internal Medicine, Winterstein and colleagues report a retrospective active-comparator cohort study using United States commercial and Medicaid claims data [3]. They examined first-trimester oral doxycycline fills in more than 218,000 pregnancies with respiratory tract infection and about 6,600 with acne, matching exposed pregnancies on propensity score and gestational age to pregnancies exposed to amoxicillin, a macrolide, or topical clindamycin. For respiratory infection, doxycycline was associated with a roughly forty to fifty percent higher risk of pregnancy loss compared with amoxicillin, and a similar increase compared with macrolides, consistently in both databases. In the acne cohorts, the comparison with topical clindamycin was statistically significant in the commercial data but not in Medicaid. Where the associations were significant, absolute risk differences ranged from 7 to 11 percentage points. The authors acknowledge possible residual confounding and misclassification of exposure or outcome, and congenital malformations were not evaluated. As an observational study it cannot establish causation, though replication across two databases and two comparators strengthens the signal. It adds population-level data on a drug commonly prescribed to women of reproductive age, where safety evidence in pregnancy has been limited.

Now, four in brief.

Staying with hypertension, The Lancet Global Health reports a cluster-randomised non-inferiority trial from Gerber and colleagues in 103 villages in rural Lesotho, enrolling 807 adults whose hypertension was already treated and controlled [4]. Community health workers who independently prescribed and titrated a fixed amlodipine and hydrochlorothiazide combination pill, with clinical decision support, were compared with usual nurse-led facility care. At twelve months, blood pressure remained controlled in about 78 percent of the intervention group and 74 percent of the control group, meeting non-inferiority. Serious adverse events were similar. This is a single trial in one setting, with mostly female participants who were already controlled at entry.

In the BMJ, Yang and colleagues ran a double-blind, placebo-controlled trial at five tertiary hospitals in China in about 2000 patients aged 60 to 80 taking an ACE inhibitor or angiotensin receptor blocker before non-cardiac surgery under general anaesthesia [5]. Replacing the morning dose with placebo lowered perioperative hypotension from about 46 percent to about 31 percent, an absolute reduction of about 14 points, and reduced vasopressor use. Thirty-day complications and mortality did not differ significantly. The design is rigorous, though the primary outcome is a physiological one and the population was limited to older patients in tertiary Chinese centres.

JAMA Internal Medicine has a stepped-wedge cluster randomised trial by Fujita and colleagues in six Australian public hospitals, involving 4827 inpatients aged 65 and older taking anticholinergic or sedative drugs [6]. A bundle of automated Drug Burden Index scores in the electronic record, deprescribing guides and stewardship pharmacists raised the proportion of patients with at least one such drug stopped or reduced by about five percentage points, less than the authors hypothesised. Deprescribing recommendations in discharge summaries also rose. The gain was not sustained once the pharmacist component ended, and in-hospital adverse events were similar across phases.

In Nature Medicine, Green and colleagues randomised 120 adults with overweight or obesity, all taking tirzepatide, to resistance exercise three times weekly or usual activities for 40 weeks [7]. Weight loss was similar, at about 22 kilograms in each arm, and fat loss did not differ. Resistance exercise reduced lean soft tissue loss by about a kilogram, and muscle strength rose with exercise while it fell with tirzepatide alone. Adherence to exercise was 91 percent. This is a small single trial with body composition and strength endpoints, and the abstract does not report functional or clinical outcomes.

Three quick signals.

In the Journal of the American Board of Family Medicine, Lynn and colleagues state that vaginal swabs are the most sensitive specimen for detecting gonorrhea and chlamydia in female patients, and argue against urine testing without a compelling reason [8]. This is a brief practice recommendation, and the abstract presents no new data.

Annals of Family Medicine carries a special report by Rubinstein and colleagues on blood-based multicancer detection tests [9]. It finds the evidence immature, with a systematic review showing insufficient data on mortality, detection outcomes or quality of life, while uptake grows through industry and health-system programmes. It is a narrative synthesis rather than new trial data.

In BJGP Open, Kozmér and colleagues interviewed 26 primary care professionals and people with lived experience of binge eating disorder or bulimia nervosa in the United Kingdom [10]. Participants called for specific education, primary care screening tools, clearer referral pathways and co-designed national guidelines. The sample is small and qualitative, so it generates priorities rather than testing them.

Stepping back across this week's papers, the strongest evidence comes from large randomised trials, yet even there the same intervention reduced events in one high-risk population and showed no clear benefit in another, so a target proven in one group does not automatically transfer to the next. Several other studies rest on surrogate or process endpoints such as body composition, intraoperative blood pressure or deprescribing rates, and the pregnancy safety signal comes from claims data where confounding cannot be excluded.

If you only have time for one paper this week, make it OPTIMAL-STROKE [1]. It provides randomised evidence on how low the systolic target should sit after stroke or transient ischaemic attack, a question managed largely in primary care, and its contrast with the diabetes trial reopens whether one target fits all high-risk patients.

That's your roundup for This Week in Family Medicine. The full transcript and references are available on the episode page. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.

Get Family Medicine every week

By email, Spotify, Apple or any podcast app.

Listen on Apple PodcastsListen on Spotify

Spot something worth flagging?